Current situation and prospect of interventional therapy for congenital heart disease in China_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

YAN Yiming ^1,2,3,4 , OUYANG Wenbin ^1,2,3,4 , ZHANG Fengwen ^1,2,3,4 , FANG Fang ^1,2,3,4 ,  PAN Xiangbin ^1,2,3,4

1. Department of Structural Heart Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, P. R. China;
2. National Health Commission Key Laboratory of Cardiovascular Regeneration Medicine, Beijing, 100037, P. R. China;
3. Key Laboratory of Innovative Cardiovascular Devices, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China;
4. National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China;

Corresponding author：

PAN Xiangbin, Email: panxiangbin@fuwaihospital.org

Keywords：

Congenital heart disease; interventional therapy; occluder device; commentary

DOI：

10.7507/1007-4848.202205081

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Transcatheter intervention for congenital heart disease has been developed for 40 years in China, it has experienced the transition of learning to self-dependent innovation, and witnessed the intervention therapy system starting from scratch and gradually reaching the top level and gaining high achievements in the world scale. With the continuous development of interventional technology and devices, cutting-edge ideas and viewpoints are constantly discussed. This review summarized the development of intervention techniques and devices, hoping to provide some experience for the further development of transcatheter interventions for congenial heart disease.

Citation： YAN Yiming, OUYANG Wenbin, ZHANG Fengwen, FANG Fang, PAN Xiangbin. Current situation and prospect of interventional therapy for congenital heart disease in China. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(10): 1243-1253. doi: 10.7507/1007-4848.202205081 Copy

1.	van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J Am Coll Cardiol, 2011, 58(21): 2241-2247.
2.	Zhao L, Chen L, Yang T, et al. Birth prevalence of congenital heart disease in China, 1980-2019: A systematic review and meta-analysis of 617 studies. Eur J Epidemiol, 2020, 35(7): 631-642.
3.	国家心血管病中心. 中国心血管病报告 2018. 北京: 中国大百科全书出版社, 2019. 1-100.
4.	潘湘斌. 超声引导经皮介入治疗结构性心脏病的探索和发展前景. 中国胸心血管外科临床杂志, 2018, 25(5): 359-361.
5.	国家心血管病医疗质量控制中心. 《2021年中国心血管病医疗质量报告》概要. 中国循环杂志, 2021, 36(11): 1041-1064.
6.	Forssmann W. Die sondierung des rechten herzens. Klinische Wochenschrift, 1929, 8(45): 2085-2087.
7.	Raju TN. The Nobel chronicles1956: Werner Forssmann (1904-79); André Frédéric Cournand (1895-1988); and Dickinson Woodruff Richards, Jr (1895-1973). Lancet, 1999, 353(9167): 1891.
8.	Bougas J, Goldberg H, Musser BG. Left heart catheterization. Ⅰ. Clinical methods and applications. Am Heart J, 1956, 52(3): 359-368.
9.	Rashkind WJ. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries. JAMA, 1966, 196(11): 991-992.
10.	周爱卿, 王荣发, 高伟, 等. 复杂性先天性心脏病的介入治疗. 中华儿科杂志, 2004, 42(11): 813-816.
11.	Porstmann W, Wierny L. Percutaneous transfemoral closure of the patent ductus arteriosus—An alternative to surgery. Semin Roentgenol, 1981, 16(2): 95-102.
12.	钱晋卿, 谢亚藩, 沈维英, 等. 非开胸法关闭动脉导管130例报告. 中华心血管病杂志, 1992, 20(3): 167-168.
13.	钱梓静, 王舒, 钱晋卿, 等. 动脉导管未闭堵塞术18例报告. 中华放射学杂志, 1987, 21(5): 282-285.
14.	King TD, Thompson SL, Steiner C, et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA, 1976, 235(23): 2506-2509.
15.	Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J, 2021, 42(6): 563-645.
16.	Vaidyanathan B, Simpson JM, Kumar RK. Transesophageal echocardiography for device closure of atrial septal defects. JACC Cardiovasc Imaging, 2009, 2(10): 1238-1242.
17.	Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J, 2007, 153(4 Suppl): 81-84.
18.	Kan JS, White RI, Mitchell SE, et al. Percutaneous balloon valvuloplasty: A new method for treating congenital pulmonary-valve stenosis. N Engl J Med, 1982, 307(9): 540-542.
19.	毛继文, 王锦志, 齐向前, 等. 经皮球囊导管肺动脉瓣成形术血液动力学的初步结果. 临床心血管病杂志, 1987, 3(2): 66-68.
20.	Reidy JF, Sowton E, Ross DN. Transcatheter occlusion of coronary to bronchial anastomosis by detachable balloon combined with coronary angioplasty at same procedure. Br Heart J, 1983, 49(3): 284-287.
21.	Lock JE, Block PC, McKay RG, et al. Transcatheter closure of ventricular septal defects. Circulation, 1988, 78(2): 361-368.
22.	秦永文, 丁仲如. 室间隔缺损的介入治疗及评价. 中国医师进修杂志, 2007, 30(1): 8-10.
23.	Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: A randomized controlled trial. J Am Coll Cardiol, 2014, 63(12): 1159-1168.
24.	Santhanam H, Yang L, Chen Z, et al. A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol, 2018, 254: 75-83.
25.	Weryński P, Skorek P, Wójcik A, et al. Recent achievements in transcatheter closure of ventricular septal defects: A systematic review of literature and a meta-analysis. Kardiol Pol, 2021, 79(2): 161-169.
26.	Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation, 1992, 86(6): 1902-1908.
27.	Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med, 2012, 366(11): 991-999.
28.	Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 2013, 368(12): 1092-1100.
29.	Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med, 2013, 368(12): 1083-1091.
30.	Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med, 2017, 377(11): 1033-1042.
31.	Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 2017, 377(11): 1011-1021.
32.	Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 2017, 377(11): 1022-1032.
33.	中国心血管健康与疾病报告2019. 心肺血管病杂志, 2020, 39(10): 1157-1162.
34.	国家卫生健康委员会国家结构性心脏病介入质量控制中心,国家心血管病中心结构性心脏病介入质量控制中心,中华医学会心血管病学分会先心病经皮介入治疗指南工作组,等. 常见先天性心脏病经皮介入治疗指南(2021版). 中华医学杂志, 2021, 101(38): 3054-3076.
35.	Sharafuddin MJ, Gu X, Titus JL, et al. Experimental evaluation of a new self-expanding patent ductus arteriosus occluder in a canine model. J Vasc Interv Radiol, 1996, 7(6): 877-887.
36.	Sharafuddin MJ A, Gu X, Titus JL, et al. Transvenous closure of secundum atrial septal defects: Preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation, 1997, 95(8): 2162-2168.
37.	Thanopoulos BD, Laskari CV, Tsaousis GS, et al. Closure of atrial septal defects with the Amplatzer occlusion device: Preliminary results. J Am Coll Cardiol, 1998, 31(5): 1110-1116.
38.	Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, et al. Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: Initial clinical applications in children. J Am Coll Cardiol, 1999, 33(5): 1395-1399.
39.	戴汝平, 刘延玲, 张戈军,等. 应用Amplatzer封堵器介入治疗房间隔缺损疗效评价(附60例报告). 中华心血管病杂志, 2000, 28(2): 87.
40.	蒋世良. 中国先天性心脏病介入治疗现状. 中国实用内科杂志, 2013, 33(4): 259-262.
41.	庞程程, 潘微, 张智伟, 等. 室间隔完整的严重肺动脉瓣狭窄或闭锁胎儿心脏介入治疗二例. 中华儿科杂志, 2018, 56(6): 445-450.
42.	张戈军, 戴汝平, 刘延玲, 等. 房间隔缺损直径的各种测量方法在介入治疗中应用价值. 中国介入心脏病学杂志, 2000, 8(4): 19-22.
43.	Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol, 2004, 44(9): 1780-1785.
44.	Hellenbrand WE, Fahey JT, McGowan FX, et al. Transesophageal echocardiographic guidance of transcatheter closure of atrial septal defect. Am J Cardiol, 1990, 66(2): 207-213.
45.	Kardon RE, Sokoloski MC, Levi DS, et al. Transthoracic echocardiographic guidance of transcatheter atrial septal defect closure. Am J Cardiol, 2004, 94(2): 256-260.
46.	潘湘斌, 逄坤静, 胡盛寿, 等. 经食管超声心动图引导下介入治疗房间隔缺损幼儿的有效性和安全性. 中华心血管病杂志, 2013, 41(9): 744-746.
47.	潘湘斌, 逄坤静, 欧阳文斌, 等. 单纯超声心动图引导下经皮室间隔缺损封堵术的应用研究. 中国循环杂志, 2015, 30(8): 774-776.
48.	潘湘斌, 欧阳文斌, 李守军, 等. 单纯超声心动图引导下行动脉导管未闭封堵术的安全性和有效性. 中华心血管病杂志, 2015, 43(1): 31-33.
49.	Yang T, Butera G, Ou-Yang WB, et al. Percutaneous closure of patent foramen ovale under transthoracic echocardiography guidance-midterm results. J Thorac Dis, 2019, 11(6): 2297-2304.
50.	潘湘斌, 胡盛寿, 欧阳文斌, 等. 单纯超声引导下经皮肺动脉瓣球囊成形术的应用研究. 中华小儿外科杂志, 2015, 36(4): 286-288.
51.	Kong P, Zhao G, Zhang Z, et al. Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial. Circ Cardiovasc Interv, 2020, 13(9): e009281.
52.	Liu Y, Guo GL, Zhang FW, et al. A novel wire is effective for echo-guiding percutaneous atrial septal defect closure: A preclinical study. J Healthc Eng, 2018, 2018: 5784567.
53.	Ovaert C, Bonnet D, Malekzadeh-Milani S. Letter by Ovaert et al regarding article, "Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial". Circ Cardiovasc Interv, 2020, 13(11): e010121.
54.	Wang C, Zhang F, Ouyang W, et al. Transcatheter closure of patent ductus arteriosus under echocardiography guidance: A randomized controlled noninferiority trial. J Interv Cardiol, 2020, 2020: 4357017.
55.	国家卫生健康委员会国家心外介入质控专家组, 国家心血管病中心医疗质量控制中心心外介入专家组. 单纯超声心动图引导经皮介入技术中国专家共识. 中国循环杂志, 2018, 33(10): 943-952.
56.	Antoniades C, Asselbergs FW, Vardas P. The year in cardiovascular medicine 2020: Digital health and innovation. Eur Heart J, 2021, 42(7): 732-739.
57.	Arnaout R, Curran L, Zhao Y, et al. An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease. Nat Med, 2021, 27(5): 882-891.
58.	Morris SA, Lopez KN. Deep learning for detecting congenital heart disease in the fetus. Nat Med, 2021, 27(5): 764-765.
59.	李林林, 于振坤, 樊红光, 等. 虚拟现实技术在心血管外科手术教学培训中的初步应用研究. 中国循环杂志, 2019, 34(3): 289-294.
60.	Vukicevic M, Mosadegh B, Min JK, et al. Cardiac 3D printing and its future directions. JACC Cardiovasc Imaging, 2017, 10(2): 171-184.
61.	Sigler M, Jux C. Biocompatibility of septal defect closure devices. Heart, 2007, 93(4): 444-449.
62.	Huang Y, Kong JF, Venkatraman SS. Biomaterials and design in occlusion devices for cardiac defects: A review. Acta Biomater, 2014, 10(3): 1088-1101.
63.	Zahn EM, Wilson N, Cutright W, et al. Development and testing of the Helex septal occluder, a new expanded polytetrafluoroethylene atrial septal defect occlusion system. Circulation, 2001, 104(6): 711-716.
64.	Lin C, Liu L, Liu Y, et al. Recent developments in next-generation occlusion devices. Acta Biomater, 2021, 128: 100-119.
65.	Kaulitz R, Bertram H, Peuster M, et al. Transcatheter closure of atrial septal defects with the CardioSEAL occluder. Z Kardiol, 2002, 91(2): 169-177.
66.	Nugent AW, Britt A, Gauvreau K, et al. Device closure rates of simple atrial septal defects optimized by the STARFlex device. J Am Coll Cardiol, 2006, 48(3): 538-544.
67.	Rao PS, Sideris EB, Haddad J, et al. Transcatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial clinical experience. Circulation, 1993, 88(3): 1119-1126.
68.	Majunke N, Sievert H. ASD/PFO devices: what is in the pipeline? J Interv Cardiol, 2007, 20(6): 517-523.
69.	Gruenstein DH, Ebeid M, Radtke W, et al. Transcatheter closure of patent ductus arteriosus using the AMPLATZER™ duct occluder Ⅱ (ADO Ⅱ). Catheter Cardiovasc Interv, 2017, 89(6): 1118-1128.
70.	Numan M, El Sisi A, Tofeig M, et al. Cribriform amplatzer device closure of fenestrated atrial septal defects: Feasibility and technical aspects. Pediatr Cardiol, 2008, 29(3): 530-535.
71.	Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheterization and Cardiovascular Interventions, 2011, 77(2): 252-259.
72.	Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheter Cardiovasc Interv, 2011, 77(2): 252-259.
73.	张戈军, 徐仲英, 蒋世良, 等. 第二代Amplatzer动脉导管未闭封堵器经股动脉逆行插管行室间隔缺损封堵术疗效评价. 临床荟萃, 2015, 30(6): 601-604.
74.	Haddad RN, Daou L, Saliba Z. Device closure of perimembranous ventricular septal defect: Choosing between amplatzer occluders. Front Pediatr, 2019, 7: 300.
75.	Holzer R, de Giovanni J, Walsh KP, et al. Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry. Catheter Cardiovasc Interv, 2006, 68(4): 620-628.
76.	Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: Early and long-term results. J Am Coll Cardiol, 2007, 50(12): 1189-1195.
77.	Zuo J, Xie J, Yi W, et al. Results of transcatheter closure of perimembranous ventricular septal defect. Am J Cardiol, 2010, 106(7): 1034-1037.
78.	Yang J, Yang L, Wan Y, et al. Transcatheter device closure of perimembranous ventricular septal defects: Mid-term outcomes. Eur Heart J, 2010, 31(18): 2238-2245.
79.	李俊杰, 张智伟, 钱明阳, 等. 应用偏心型和对称型封堵器介入治疗小儿膜周部室间隔缺损的对比研究. 中国介入心脏病学杂志, 2009, 17(6): 301-304.
80.	秦永文, 赵仙先, 徐荣良, 等. 应用自制封堵器经导管闭合膜部室间隔缺损. 中华心血管病杂志, 2003, 31(1): 31.
81.	袁建华. 浅谈介入治疗技术的规范化. 介入放射学杂志, 2005, 14(4): 427-429.
82.	秦永文, 赵仙先, 吴弘, 等. 自制非对称型室间隔缺损封堵器的初步临床应用. 介入放射学杂志, 2004, 13(2): 101-103.
83.	Ou-Yang WB, Li SJ, Wang SZ, et al. Echocardiographic guided closure of perimembranous ventricular septal defects. Ann Thorac Surg, 2015, 100(4): 1398-1402.
84.	Yang K, Lyu JH, Hu HB, et al. Efficacy and safety of a parylene-coated occluder for atrial septal defect: A prospective, multi-center, randomized controlled clinical trial. Chin Med J (Engl), 2021, 134(22): 2685-2691.
85.	Esteves CA, Solarewicz LA, Cassar R, et al. Occlusion of the perimembranous ventricular septal defect using CERA® devices. Catheter Cardiovasc Interv, 2012, 80(2): 182-187.
86.	Lifeng Z, Yan H, Dayun Y, et al. The underlying biological mechanisms of biocompatibility differences between bare and TiN-coated NiTi alloys. Biomed Mater, 2011, 6(2): 025012.
87.	Kaya MG, Akpek M, Celebi A, et al. A multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defects. EuroIntervention, 2014, 10(5): 626-631.
88.	Ulmi M, Praz F, Siontis GCM, et al. Propensity-score matched comparison of the cera PFO occluder with the Amplatzer PFO occluder for percutaneous closure of patent foramen ovale without echocardiographic guidance. J Invasive Cardiol, 2017, 29(8): 280-284.
89.	Bhattacharjya S, Pillai LS, Doraiswamy V, et al. Prospective concurrent head-to head comparison of three different types of nitinol occluder device for transcatheter closure of secundum atrial septal defects. EuroIntervention, 2019, 15(4): e321-e328.
90.	Sievert K, Yu J, Bertog S, et al. Post-market clinical follow-up with the patent foramen ovale closure device IrisFIT (Lifetech) in patients with stroke, transient ischemic attack, or other thromboembolic events. Cardiovasc Revasc Med, 2021, 30: 72-75.
91.	Ramot Y, Haim-Zada M, Domb AJ, et al. Biocompatibility and safety of PLA and its copolymers. Adv Drug Deliv Rev, 2016, 107: 153-162.
92.	da Silva D, Kaduri M, Poley M, et al. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems. Chem Eng J, 2018, 340: 9-14.
93.	In vitro degradation behavior of l-lactide/trimethylene carbonate/glycolide terpolymers and a composite with poly (l-lactide-co-glycolide) fibers-ScienceDirect. [2022-05-07]. https://www.sciencedirect.com/science/article/pii/S0141391014004297.
94.	Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials, 2000, 21(23): 2335-2346.
95.	Goonoo N, Jeetah R, Bhaw-Luximon A, et al. Polydioxanone-based bio-materials for tissue engineering and drug/gene delivery applications. Eur J Pharm Biopharm, 2015, 97(Pt B): 371-391.
96.	Bartnikowski M, Dargaville T R, Ivanovski S, et al. Degradation mechanisms of polycaprolactone in the context of chemistry, geometry and environment. Progress in Polymer Science, 2019, 96: 1-20.
97.	Jux C, Bertram H, Wohlsein P, et al. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: Development and preclinical evaluation of the BioSTAR device. J Am Coll Cardiol, 2006, 48(1): 161-169.
98.	Mullen MJ, Devellian CA, Jux C. BioSTAR bioabsorbable septal repair implant. Expert Rev Med Devices, 2007, 4(6): 781-792.
99.	Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): A prospective, multicenter, phaseⅠclinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation, 2006, 114(18): 1962-1967.
100.	Morgan G, Lee KJ, Chaturvedi R, et al. A biodegradable device (BioSTAR) for atrial septal defect closure in children. Catheter Cardiovasc Interv, 2010, 76(2): 241-245.
101.	Baspinar O, Kervancioglu M, Kilinc M, et al. Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children. Tex Heart Inst J, 2012, 39(2): 184-189.
102.	Sigler M, Söderberg B, Schmitt B, et al. Carag bioresorbable septal occluder (CBSO): Histopathology of experimental implants. EuroIntervention, 2018, 13(14): 1655-1661.
103.	Liu SJ, Peng KM, Hsiao CY, et al. Novel biodegradable polycaprolactone occlusion device combining nanofibrous PLGA/collagen membrane for closure of atrial septal defect (ASD). Ann Biomed Eng, 2011, 39(11): 2759-2766.
104.	Zhu YF, Huang XM, Cao J, et al. Animal experimental study of the fully biodegradable atrial septal defect (ASD) occluder. J Biomed Biotechnol, 2012, 2012: 735989.
105.	Huang XM, Zhu YF, Cao J, et al. Development and preclinical evaluation of a biodegradable ventricular septal defect occluder. Catheter Cardiovasc Interv, 2013, 81(2): 324-330.
106.	Li YF, Xie YM, Chen J, et al. Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: From preclinical study to first-in-human experience. Catheter Cardiovasc Interv, 2020, 95(2): 282-293.
107.	Lin C, Lv J, Li Y, et al. 4D-printed biodegradable and remotely controllable shape memory occlusion devices. Adv Funct Mater, 2019, 29(51): 1906569.
108.	Lu W, Ouyang W, Wang S, et al. A novel totally biodegradable device for effective atrial septal defect closure: A 2-year study in sheep. J Interv Cardiol, 2018, 31(6): 841-848.
109.	张凤文, 孙毅, 潘湘斌, 等. 完全可降解封堵器治疗膜周部室间隔缺损两例. 中国胸心血管外科临床杂志, 2018, 25(7): 636-638.

1. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J Am Coll Cardiol, 2011, 58(21): 2241-2247.
2. Zhao L, Chen L, Yang T, et al. Birth prevalence of congenital heart disease in China, 1980-2019: A systematic review and meta-analysis of 617 studies. Eur J Epidemiol, 2020, 35(7): 631-642.
3. 国家心血管病中心. 中国心血管病报告 2018. 北京: 中国大百科全书出版社, 2019. 1-100.
4. 潘湘斌. 超声引导经皮介入治疗结构性心脏病的探索和发展前景. 中国胸心血管外科临床杂志, 2018, 25(5): 359-361.
5. 国家心血管病医疗质量控制中心. 《2021年中国心血管病医疗质量报告》概要. 中国循环杂志, 2021, 36(11): 1041-1064.
6. Forssmann W. Die sondierung des rechten herzens. Klinische Wochenschrift, 1929, 8(45): 2085-2087.
7. Raju TN. The Nobel chronicles1956: Werner Forssmann (1904-79); André Frédéric Cournand (1895-1988); and Dickinson Woodruff Richards, Jr (1895-1973). Lancet, 1999, 353(9167): 1891.
8. Bougas J, Goldberg H, Musser BG. Left heart catheterization. Ⅰ. Clinical methods and applications. Am Heart J, 1956, 52(3): 359-368.
9. Rashkind WJ. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries. JAMA, 1966, 196(11): 991-992.
10. 周爱卿, 王荣发, 高伟, 等. 复杂性先天性心脏病的介入治疗. 中华儿科杂志, 2004, 42(11): 813-816.
11. Porstmann W, Wierny L. Percutaneous transfemoral closure of the patent ductus arteriosus—An alternative to surgery. Semin Roentgenol, 1981, 16(2): 95-102.
12. 钱晋卿, 谢亚藩, 沈维英, 等. 非开胸法关闭动脉导管130例报告. 中华心血管病杂志, 1992, 20(3): 167-168.
13. 钱梓静, 王舒, 钱晋卿, 等. 动脉导管未闭堵塞术18例报告. 中华放射学杂志, 1987, 21(5): 282-285.
14. King TD, Thompson SL, Steiner C, et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA, 1976, 235(23): 2506-2509.
15. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J, 2021, 42(6): 563-645.
16. Vaidyanathan B, Simpson JM, Kumar RK. Transesophageal echocardiography for device closure of atrial septal defects. JACC Cardiovasc Imaging, 2009, 2(10): 1238-1242.
17. Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J, 2007, 153(4 Suppl): 81-84.
18. Kan JS, White RI, Mitchell SE, et al. Percutaneous balloon valvuloplasty: A new method for treating congenital pulmonary-valve stenosis. N Engl J Med, 1982, 307(9): 540-542.
19. 毛继文, 王锦志, 齐向前, 等. 经皮球囊导管肺动脉瓣成形术血液动力学的初步结果. 临床心血管病杂志, 1987, 3(2): 66-68.
20. Reidy JF, Sowton E, Ross DN. Transcatheter occlusion of coronary to bronchial anastomosis by detachable balloon combined with coronary angioplasty at same procedure. Br Heart J, 1983, 49(3): 284-287.
21. Lock JE, Block PC, McKay RG, et al. Transcatheter closure of ventricular septal defects. Circulation, 1988, 78(2): 361-368.
22. 秦永文, 丁仲如. 室间隔缺损的介入治疗及评价. 中国医师进修杂志, 2007, 30(1): 8-10.
23. Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: A randomized controlled trial. J Am Coll Cardiol, 2014, 63(12): 1159-1168.
24. Santhanam H, Yang L, Chen Z, et al. A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol, 2018, 254: 75-83.
25. Weryński P, Skorek P, Wójcik A, et al. Recent achievements in transcatheter closure of ventricular septal defects: A systematic review of literature and a meta-analysis. Kardiol Pol, 2021, 79(2): 161-169.
26. Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation, 1992, 86(6): 1902-1908.
27. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med, 2012, 366(11): 991-999.
28. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 2013, 368(12): 1092-1100.
29. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med, 2013, 368(12): 1083-1091.
30. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med, 2017, 377(11): 1033-1042.
31. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 2017, 377(11): 1011-1021.
32. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 2017, 377(11): 1022-1032.
33. 中国心血管健康与疾病报告2019. 心肺血管病杂志, 2020, 39(10): 1157-1162.
34. 国家卫生健康委员会国家结构性心脏病介入质量控制中心,国家心血管病中心结构性心脏病介入质量控制中心,中华医学会心血管病学分会先心病经皮介入治疗指南工作组,等. 常见先天性心脏病经皮介入治疗指南(2021版). 中华医学杂志, 2021, 101(38): 3054-3076.
35. Sharafuddin MJ, Gu X, Titus JL, et al. Experimental evaluation of a new self-expanding patent ductus arteriosus occluder in a canine model. J Vasc Interv Radiol, 1996, 7(6): 877-887.
36. Sharafuddin MJ A, Gu X, Titus JL, et al. Transvenous closure of secundum atrial septal defects: Preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation, 1997, 95(8): 2162-2168.
37. Thanopoulos BD, Laskari CV, Tsaousis GS, et al. Closure of atrial septal defects with the Amplatzer occlusion device: Preliminary results. J Am Coll Cardiol, 1998, 31(5): 1110-1116.
38. Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, et al. Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: Initial clinical applications in children. J Am Coll Cardiol, 1999, 33(5): 1395-1399.
39. 戴汝平, 刘延玲, 张戈军,等. 应用Amplatzer封堵器介入治疗房间隔缺损疗效评价(附60例报告). 中华心血管病杂志, 2000, 28(2): 87.
40. 蒋世良. 中国先天性心脏病介入治疗现状. 中国实用内科杂志, 2013, 33(4): 259-262.
41. 庞程程, 潘微, 张智伟, 等. 室间隔完整的严重肺动脉瓣狭窄或闭锁胎儿心脏介入治疗二例. 中华儿科杂志, 2018, 56(6): 445-450.
42. 张戈军, 戴汝平, 刘延玲, 等. 房间隔缺损直径的各种测量方法在介入治疗中应用价值. 中国介入心脏病学杂志, 2000, 8(4): 19-22.
43. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol, 2004, 44(9): 1780-1785.
44. Hellenbrand WE, Fahey JT, McGowan FX, et al. Transesophageal echocardiographic guidance of transcatheter closure of atrial septal defect. Am J Cardiol, 1990, 66(2): 207-213.
45. Kardon RE, Sokoloski MC, Levi DS, et al. Transthoracic echocardiographic guidance of transcatheter atrial septal defect closure. Am J Cardiol, 2004, 94(2): 256-260.
46. 潘湘斌, 逄坤静, 胡盛寿, 等. 经食管超声心动图引导下介入治疗房间隔缺损幼儿的有效性和安全性. 中华心血管病杂志, 2013, 41(9): 744-746.
47. 潘湘斌, 逄坤静, 欧阳文斌, 等. 单纯超声心动图引导下经皮室间隔缺损封堵术的应用研究. 中国循环杂志, 2015, 30(8): 774-776.
48. 潘湘斌, 欧阳文斌, 李守军, 等. 单纯超声心动图引导下行动脉导管未闭封堵术的安全性和有效性. 中华心血管病杂志, 2015, 43(1): 31-33.
49. Yang T, Butera G, Ou-Yang WB, et al. Percutaneous closure of patent foramen ovale under transthoracic echocardiography guidance-midterm results. J Thorac Dis, 2019, 11(6): 2297-2304.
50. 潘湘斌, 胡盛寿, 欧阳文斌, 等. 单纯超声引导下经皮肺动脉瓣球囊成形术的应用研究. 中华小儿外科杂志, 2015, 36(4): 286-288.
51. Kong P, Zhao G, Zhang Z, et al. Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial. Circ Cardiovasc Interv, 2020, 13(9): e009281.
52. Liu Y, Guo GL, Zhang FW, et al. A novel wire is effective for echo-guiding percutaneous atrial septal defect closure: A preclinical study. J Healthc Eng, 2018, 2018: 5784567.
53. Ovaert C, Bonnet D, Malekzadeh-Milani S. Letter by Ovaert et al regarding article, "Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial". Circ Cardiovasc Interv, 2020, 13(11): e010121.
54. Wang C, Zhang F, Ouyang W, et al. Transcatheter closure of patent ductus arteriosus under echocardiography guidance: A randomized controlled noninferiority trial. J Interv Cardiol, 2020, 2020: 4357017.
55. 国家卫生健康委员会国家心外介入质控专家组, 国家心血管病中心医疗质量控制中心心外介入专家组. 单纯超声心动图引导经皮介入技术中国专家共识. 中国循环杂志, 2018, 33(10): 943-952.
56. Antoniades C, Asselbergs FW, Vardas P. The year in cardiovascular medicine 2020: Digital health and innovation. Eur Heart J, 2021, 42(7): 732-739.
57. Arnaout R, Curran L, Zhao Y, et al. An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease. Nat Med, 2021, 27(5): 882-891.
58. Morris SA, Lopez KN. Deep learning for detecting congenital heart disease in the fetus. Nat Med, 2021, 27(5): 764-765.
59. 李林林, 于振坤, 樊红光, 等. 虚拟现实技术在心血管外科手术教学培训中的初步应用研究. 中国循环杂志, 2019, 34(3): 289-294.
60. Vukicevic M, Mosadegh B, Min JK, et al. Cardiac 3D printing and its future directions. JACC Cardiovasc Imaging, 2017, 10(2): 171-184.
61. Sigler M, Jux C. Biocompatibility of septal defect closure devices. Heart, 2007, 93(4): 444-449.
62. Huang Y, Kong JF, Venkatraman SS. Biomaterials and design in occlusion devices for cardiac defects: A review. Acta Biomater, 2014, 10(3): 1088-1101.
63. Zahn EM, Wilson N, Cutright W, et al. Development and testing of the Helex septal occluder, a new expanded polytetrafluoroethylene atrial septal defect occlusion system. Circulation, 2001, 104(6): 711-716.
64. Lin C, Liu L, Liu Y, et al. Recent developments in next-generation occlusion devices. Acta Biomater, 2021, 128: 100-119.
65. Kaulitz R, Bertram H, Peuster M, et al. Transcatheter closure of atrial septal defects with the CardioSEAL occluder. Z Kardiol, 2002, 91(2): 169-177.
66. Nugent AW, Britt A, Gauvreau K, et al. Device closure rates of simple atrial septal defects optimized by the STARFlex device. J Am Coll Cardiol, 2006, 48(3): 538-544.
67. Rao PS, Sideris EB, Haddad J, et al. Transcatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial clinical experience. Circulation, 1993, 88(3): 1119-1126.
68. Majunke N, Sievert H. ASD/PFO devices: what is in the pipeline? J Interv Cardiol, 2007, 20(6): 517-523.
69. Gruenstein DH, Ebeid M, Radtke W, et al. Transcatheter closure of patent ductus arteriosus using the AMPLATZER™ duct occluder Ⅱ (ADO Ⅱ). Catheter Cardiovasc Interv, 2017, 89(6): 1118-1128.
70. Numan M, El Sisi A, Tofeig M, et al. Cribriform amplatzer device closure of fenestrated atrial septal defects: Feasibility and technical aspects. Pediatr Cardiol, 2008, 29(3): 530-535.
71. Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheterization and Cardiovascular Interventions, 2011, 77(2): 252-259.
72. Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheter Cardiovasc Interv, 2011, 77(2): 252-259.
73. 张戈军, 徐仲英, 蒋世良, 等. 第二代Amplatzer动脉导管未闭封堵器经股动脉逆行插管行室间隔缺损封堵术疗效评价. 临床荟萃, 2015, 30(6): 601-604.
74. Haddad RN, Daou L, Saliba Z. Device closure of perimembranous ventricular septal defect: Choosing between amplatzer occluders. Front Pediatr, 2019, 7: 300.
75. Holzer R, de Giovanni J, Walsh KP, et al. Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry. Catheter Cardiovasc Interv, 2006, 68(4): 620-628.
76. Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: Early and long-term results. J Am Coll Cardiol, 2007, 50(12): 1189-1195.
77. Zuo J, Xie J, Yi W, et al. Results of transcatheter closure of perimembranous ventricular septal defect. Am J Cardiol, 2010, 106(7): 1034-1037.
78. Yang J, Yang L, Wan Y, et al. Transcatheter device closure of perimembranous ventricular septal defects: Mid-term outcomes. Eur Heart J, 2010, 31(18): 2238-2245.
79. 李俊杰, 张智伟, 钱明阳, 等. 应用偏心型和对称型封堵器介入治疗小儿膜周部室间隔缺损的对比研究. 中国介入心脏病学杂志, 2009, 17(6): 301-304.
80. 秦永文, 赵仙先, 徐荣良, 等. 应用自制封堵器经导管闭合膜部室间隔缺损. 中华心血管病杂志, 2003, 31(1): 31.
81. 袁建华. 浅谈介入治疗技术的规范化. 介入放射学杂志, 2005, 14(4): 427-429.
82. 秦永文, 赵仙先, 吴弘, 等. 自制非对称型室间隔缺损封堵器的初步临床应用. 介入放射学杂志, 2004, 13(2): 101-103.
83. Ou-Yang WB, Li SJ, Wang SZ, et al. Echocardiographic guided closure of perimembranous ventricular septal defects. Ann Thorac Surg, 2015, 100(4): 1398-1402.
84. Yang K, Lyu JH, Hu HB, et al. Efficacy and safety of a parylene-coated occluder for atrial septal defect: A prospective, multi-center, randomized controlled clinical trial. Chin Med J (Engl), 2021, 134(22): 2685-2691.
85. Esteves CA, Solarewicz LA, Cassar R, et al. Occlusion of the perimembranous ventricular septal defect using CERA® devices. Catheter Cardiovasc Interv, 2012, 80(2): 182-187.
86. Lifeng Z, Yan H, Dayun Y, et al. The underlying biological mechanisms of biocompatibility differences between bare and TiN-coated NiTi alloys. Biomed Mater, 2011, 6(2): 025012.
87. Kaya MG, Akpek M, Celebi A, et al. A multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defects. EuroIntervention, 2014, 10(5): 626-631.
88. Ulmi M, Praz F, Siontis GCM, et al. Propensity-score matched comparison of the cera PFO occluder with the Amplatzer PFO occluder for percutaneous closure of patent foramen ovale without echocardiographic guidance. J Invasive Cardiol, 2017, 29(8): 280-284.
89. Bhattacharjya S, Pillai LS, Doraiswamy V, et al. Prospective concurrent head-to head comparison of three different types of nitinol occluder device for transcatheter closure of secundum atrial septal defects. EuroIntervention, 2019, 15(4): e321-e328.
90. Sievert K, Yu J, Bertog S, et al. Post-market clinical follow-up with the patent foramen ovale closure device IrisFIT (Lifetech) in patients with stroke, transient ischemic attack, or other thromboembolic events. Cardiovasc Revasc Med, 2021, 30: 72-75.
91. Ramot Y, Haim-Zada M, Domb AJ, et al. Biocompatibility and safety of PLA and its copolymers. Adv Drug Deliv Rev, 2016, 107: 153-162.
92. da Silva D, Kaduri M, Poley M, et al. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems. Chem Eng J, 2018, 340: 9-14.
93. In vitro degradation behavior of l-lactide/trimethylene carbonate/glycolide terpolymers and a composite with poly (l-lactide-co-glycolide) fibers-ScienceDirect. [2022-05-07]. https://www.sciencedirect.com/science/article/pii/S0141391014004297.
94. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials, 2000, 21(23): 2335-2346.
95. Goonoo N, Jeetah R, Bhaw-Luximon A, et al. Polydioxanone-based bio-materials for tissue engineering and drug/gene delivery applications. Eur J Pharm Biopharm, 2015, 97(Pt B): 371-391.
96. Bartnikowski M, Dargaville T R, Ivanovski S, et al. Degradation mechanisms of polycaprolactone in the context of chemistry, geometry and environment. Progress in Polymer Science, 2019, 96: 1-20.
97. Jux C, Bertram H, Wohlsein P, et al. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: Development and preclinical evaluation of the BioSTAR device. J Am Coll Cardiol, 2006, 48(1): 161-169.
98. Mullen MJ, Devellian CA, Jux C. BioSTAR bioabsorbable septal repair implant. Expert Rev Med Devices, 2007, 4(6): 781-792.
99. Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): A prospective, multicenter, phaseⅠclinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation, 2006, 114(18): 1962-1967.
100. Morgan G, Lee KJ, Chaturvedi R, et al. A biodegradable device (BioSTAR) for atrial septal defect closure in children. Catheter Cardiovasc Interv, 2010, 76(2): 241-245.
101. Baspinar O, Kervancioglu M, Kilinc M, et al. Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children. Tex Heart Inst J, 2012, 39(2): 184-189.
102. Sigler M, Söderberg B, Schmitt B, et al. Carag bioresorbable septal occluder (CBSO): Histopathology of experimental implants. EuroIntervention, 2018, 13(14): 1655-1661.
103. Liu SJ, Peng KM, Hsiao CY, et al. Novel biodegradable polycaprolactone occlusion device combining nanofibrous PLGA/collagen membrane for closure of atrial septal defect (ASD). Ann Biomed Eng, 2011, 39(11): 2759-2766.
104. Zhu YF, Huang XM, Cao J, et al. Animal experimental study of the fully biodegradable atrial septal defect (ASD) occluder. J Biomed Biotechnol, 2012, 2012: 735989.
105. Huang XM, Zhu YF, Cao J, et al. Development and preclinical evaluation of a biodegradable ventricular septal defect occluder. Catheter Cardiovasc Interv, 2013, 81(2): 324-330.
106. Li YF, Xie YM, Chen J, et al. Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: From preclinical study to first-in-human experience. Catheter Cardiovasc Interv, 2020, 95(2): 282-293.
107. Lin C, Lv J, Li Y, et al. 4D-printed biodegradable and remotely controllable shape memory occlusion devices. Adv Funct Mater, 2019, 29(51): 1906569.
108. Lu W, Ouyang W, Wang S, et al. A novel totally biodegradable device for effective atrial septal defect closure: A 2-year study in sheep. J Interv Cardiol, 2018, 31(6): 841-848.
109. 张凤文, 孙毅, 潘湘斌, 等. 完全可降解封堵器治疗膜周部室间隔缺损两例. 中国胸心血管外科临床杂志, 2018, 25(7): 636-638.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Current situation and prospect of interventional therapy for congenital heart disease in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content